Silexion CEO granted 10,000-share RSU award
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Insider Trade Summary
Grant/Award: 10,000 shares
Grant/Award
2 txns
Insider
Hadar Ilan
Role
Chairman and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares | 10,000 | $0.00 | $0.00 |
| holding | Stock Option (right to buy Ordinary Shares) | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 16,547 shares (Direct);
Stock Option (right to buy Ordinary Shares) — 96 contracts (Direct)
Footnotes (4)
- F1. The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 65,471 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 6,547 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
- F2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
- F3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F4. The number of options to purchase ordinary shares and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 956 options to purchase 956 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person as reported in that Form 4, to become 96 options to purchase 96 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).
Key Figures
RSU grant shares: 10,000 shares
Shares held after grant: 16,547 shares
Reverse split ratio: 1-for-10
+5 more
8 metrics
RSU grant shares
10,000 shares
Fully vested RSUs immediately settled into ordinary shares
Shares held after grant
16,547 shares
Ordinary shares directly held by Hadar Ilan after award
Reverse split ratio
1-for-10
Reverse share split effected on May 28, 2026
Pre-split shares
65,471 shares
Ordinary shares beneficially owned before reverse split adjustment
Post-split base shares
6,547 shares
Adjusted ordinary shares after 1-for-10 reverse split, before new grant
Options outstanding
96 options
Stock options to buy 96 ordinary shares after reverse split adjustment
Option exercise price
$9,077.10 per share
Exercise price of adjusted stock options expiring March 24, 2032
Original options pre-split
956 options
Options to purchase 956 ordinary shares before 1-for-10 reverse split
Key Terms
reverse share split, restricted share units (RSUs), beneficially owned, exercise price, +1 more
5 terms
beneficially owned financial
"beneficially owned by the Reporting Person as reported in that Form 4"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
exercise price financial
"at an exercise price of $9,077.10 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
stock option financial
"Stock Option (right to buy Ordinary Shares)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Silexion Therapeutics (SLXN) report for Hadar Ilan?
Silexion reported that Chairman and CEO Hadar Ilan received 10,000 ordinary shares via fully vested RSUs, granted as compensation for services as an officer and approved by the board. This non-cash award increased Ilan’s direct holdings to 16,547 ordinary shares.
What was the size and nature of the equity award to Silexion (SLXN) CEO Hadar Ilan?
Hadar Ilan received a grant of 10,000 ordinary shares through fully vested restricted share units that were immediately settled into shares. The award was approved by Silexion’s board of directors and compensates Ilan for services as an officer rather than an open-market share purchase.
What stock options does Silexion (SLXN) CEO Hadar Ilan hold after this filing?
The filing shows Hadar Ilan holds 96 stock options, each for one ordinary share, with an exercise price of $9,077.10 per share and an expiration date of March 24, 2032. These option figures were adjusted to reflect Silexion’s 1-for-10 reverse share split on May 28, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates